Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1

This publication has 17 references indexed in Scilit:

• Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin
  New England Journal of Medicine, 2023
• Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
  The Lancet Diabetes & Endocrinology, 2022
• Rationale and design of the phase 3a development programme ( ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes
  Diabetes, Obesity and Metabolism, 2022
• Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA Trial
  Canadian Journal of Diabetes, 2022
• Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing
  BMJ Open Diabetes Research & Care, 2021
• Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO , a crossover study of basal insulin‐treated adults with type 2 diabetes and risk factors for hypoglycaemia
  Diabetes, Obesity and Metabolism, 2021
• Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin
  JAMA, 2021
• Hypoglycemia: New Definitions and Regulatory Implications
  Diabetes Technology & Therapeutics, 2018
• Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature
  Journal of Diabetes Research, 2018
• Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
  New England Journal of Medicine, 2017